Add-on intravenous ketamine eliminates treatment lag period in severe non-treatment-resistant major depression: Rapid antidepressant and anti-suicidal effects – A randomized controlled trial

Anand Prakash, Pranab Mahapatra, Jigyansa I. Pattnaik, Udit K. Panda, Sudipta K. Das · 2026

Read Add-on intravenous ketamine eliminates treatment lag period in severe non-treatment-resistant major depression: Rapid antidepressant and anti-suicidal effects – A randomized controlled trial by Anand Prakash, Pranab Mahapatra, Jigyansa I. Pattnaik, Udit K. Panda, Sudipta K. Das (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13623255.txt.

Description

Standard antidepressants take four to twelve weeks to work, and suicide risk peaks in the first month, leaving severely depressed patients exposed. Ketamine has been studied mostly in treatment-resistant cases. The authors ran a double-blind randomized trial in 40 patients with severe but not treatment-resistant depression. Half received four ketamine infusions over eight days on top of standard care; half received placebo.

By day 12, 58 percent of the ketamine group had responded, against 29 percent on placebo, with gains visible from day two. Suicidal thinking cleared fully by day five in the ketamine group while it persisted on placebo. Benefits held at four weeks. One warning sign: patients with anxious features completed treatment at far lower rates. The authors call the pilot promising but in need of a larger trial.

Catalog record

CREATORAnand Prakash, Pranab Mahapatra, Jigyansa I. Pattnaik, Udit K. Panda, Sudipta K. Das
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE33 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13623255

Browse the full library · About the Tower of Babel